Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Depression is a common, devastating illness. Current pharmacotherapies help many
patients, but high rates of a partial response or no response, and the delayed onset of the …

Ketamine is a phencyclidine derivative, which functions primarily as an antagonist of the N-
methyl-d-aspartate receptor. It has no affinity for gamma-aminobutyric acid receptors in the …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

A single, low dose of the NMDA receptor antagonist ketamine produces rapid
antidepressant actions in treatment-resistant depressed patients. Understanding the cellular …

Therapeutic medications for the treatment of depression have serious limitations, particularly
delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Ketamine, a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, produces
rapid and long-lasting antidepressant effects in major depressive disorder (MDD) patients.(2 …

Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …